The firm evaluated the company's other assets and claimed "accretion does not appear robust enough to justify the current valuation," according to a research note. Sterne Agee maintained its $13 target price.
Separately, TheStreet Ratings team rates ALBANY MOLECULAR RESH INC as a "buy" with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:
"We rate ALBANY MOLECULAR RESH INC (AMRI) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins."